Hexagon Nutrition IPO

Hexagon Nutrition is gearing up for its IPO between June 5th and June 9th, seeking a valuation of ₹550 crore. Interestingly, this isn’t the company’s first attempt; they previously filed in 2021 with a higher valuation target. The fact that they are now returning at a lower valuation—without the company receiving any fresh capital as the entire proceeds go to promoters—raises serious questions about their growth strategy and the urgency behind this move. The company operates in the micronutrient and supplement space, with a diverse revenue stream spanning clinical products, daily multivitamins, and international exports affiliated with the UN. While their financials show a steady 10% revenue growth and manageable debt, there are warning signs. Trade receivables have ballooned from ₹60 crore to ₹82 crore, signaling a potential cash crunch, while their high employee attrition rate remains a persistent red flag. When compared to established players like Zydus Wellness, Hexagon’s valuation seems attractively priced on paper. However, the lack of explosive growth is the "missing link" that might explain the market's cautious stance. If you are hunting for listing gains, the current pricing offers potential value, but investors must look past the hype and weigh these structural concerns before diving in.